27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
Taiwan Liposome (NASDAQ:TLC) shares are trading higher on Monday.
The company announced the results of its TLCS590 Phase 2 Trial for its Postsurgical pain management demonstrated greater reduction in pain.
Cantor Fitzgerald also maintained its Overweight on the company and raised its price target from $10 to $12 per share.
Taiwan Liposome is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products based on its proprietary drug delivery technologies. The company offers products in therapeutic areas, such as oncology, PAD, ophthalmology, fungal infection, arthritis, and anesthetic indications
Taiwan Liposome shares were trading up 8.82% at $5.34 at time of publication on Monday. The stock has a 52-week high of $8.54 and a 52-week low of $2.48.
Related Links:
Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!